Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge
Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge
复制标题
DOI：
10.1016/j.vaccine.2009.12.062
复制
发表时间：
2010-03-08
期刊：
影响因子：
5.5
通讯作者：
Bosch, B. J.
中科院分区：
文献类型：
--
作者：
de Boer, S. M.;Kortekaas, J.;Bosch, B. J.
裂谷热病毒（RVFV）是一种新兴的蚊媒病毒，可导致牲畜和人类显着发病和死亡。裂谷热在非洲流行，但非洲大陆以外也有疫情爆发的报道。在此，我们报告了基于病毒 Gn 和 Gc 包膜糖蛋白的两种候选疫苗的评估，这两种疫苗均在果蝇昆虫细胞表达系统中产生。仅通过表达 Gn 和 Gc 糖蛋白即可产生病毒样颗粒 (VLP)。此外，从昆虫细胞培养物上清液中表达并亲和纯化了可溶形式的 Gn 胞外域。两种候选疫苗都能充分保护小鼠免受 RVFV 的致命攻击。重要的是，任一候选疫苗中都不存在核衣壳蛋白，这有助于使用基于商业重组核衣壳蛋白的间接 ELISA 区分受感染的动物和接种疫苗的动物。 (C) 2010 Elsevier Ltd. 保留所有权利。
Rift Valley fever virus (RVFV) is an emerging mosquito-borne virus causing significant morbidity and mortality in livestock and humans. Rift Valley fever is endemic in Africa, but also outside this continent outbreaks have been reported. Here we report the evaluation of two vaccine candidates based on the viral Gn and Gc envelope glycoproteins, both produced in a Drosophila insect cell expression system. Virus-like particles (VLPs) were generated by merely expressing the Gn and Gc glycoproteins. In addition, a soluble form of the Gn ectodomain was expressed and affinity-purified from the insect cell culture supernatant. Both vaccine candidates fully protected mice from a lethal challenge with RVFV. Importantly, absence of the nucleocapsid protein in either vaccine candidate facilitates the differentiation between infected and vaccinated animals using a commercial recombinant nucleocapsid protein-based indirect ELISA. (C) 2010 Elsevier Ltd. All rights reserved.